Rituximab

• The MEMORINEPH study: Memory B cell level-based tailored treatment with Rixathon in children with complicated forms of steroid-sensitive Nep… Not authorised
  2024-511214-20-00 Phase II 1 country Ospedale Pediatrico Bambino Gesu'
• A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending
  2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending
  2024-513445-37-00 Phase III 4 countries University Of Cologne
• ALLIC 2022 international clinical investigation for advanced management of childhood acute lymphoblastic leukemia Pending
  2024-513824-41-00 Phase IV 4 countries Semmelweis University
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending
  2024-516052-17-01 Phase II/III 1 country Hospital Foch
• Rituximab therapy in anti-MAG patients with characteristics of good responders: THERAMAG study Pending
  2024-516335-27-00 Phase III 1 country Centre Hospitalier Universitaire De Saint Etienne
• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending
  2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
• Chemoimmunotherapy in conjunction with blood-brain-barrier opening in patients with newly diagnosed or relapsed primary central nervous syst… Pending
  2024-519046-79-00 Phase II 1 country Oulu University Hospital
• HiHat trial Pending
  2024-519700-28-01 Phase II 1 country Region Uppsala
• A randomized controlled, two-arm (1:1 ratio) Phase IIa trial to assess the efficacy and safety of obinutuzumab in treating adults with de no… Pending
  2025-520641-69-00 Phase II 3 countries Medizinische Universitaet Innsbruck
• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 Phase II/III 1 country Assistance Publique Hopitaux De Paris
• PREP-ANCA - Comparison of a strategy based on clinic-biological surveillance versus pre-emptive treatment with rituximab in the event of ANC… Pending
  2025-522049-23-00 Phase IV 1 country Assistance Publique Hopitaux De Paris
• The REFINE study Pending
  2025-522133-66-00 Phase III 1 country Karolinska University Hospital
• A First-in-Human Trial of DS3790a in Participants with Hematological Malignancies. Pending
  2025-522595-87-00 Phase I (FiH) 2 countries Daiichi Sankyo Inc.
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 Phase III 8 countries Deciphera Pharmaceuticals Inc.
• Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept Pending
  2025-523465-21-00 Phase III 1 country Region Stockholm – SLSO
• A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment … Pending
  2025-523892-50-00 Phase III 1 country Region Stockholm – SLSO
• A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending
  2025-524241-27-00 Phase III 5 countries Innocare Pharma Inc.
• Study of BMS-986353, CD19-CAR T Cells, versus SoC in Participants with Active SSc (Breakfree-SSc) Pending
  2025-524337-11-00 Phase III 4 countries Celgene Corp.
• Phase IV VR in relapsed CLL – Polish experience Pending
  2025-524795-35-00 Phase IV 1 country Uniwersytet Medyczny W Lublinie
• Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG Pending
  2026-525324-26-00 Phase II 1 country Region Oerebro Laen
• A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) Recruiting
  2025-522777-10-00 Phase II/III 2 countries Merck Sharp & Dohme LLC
• A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting
  2025-522669-32-00 Phase III 2 countries Dizal Pharmaceutical Co. Ltd.
• A randomized controlled phase II, double blinded trial to investigate pulmonary function after treatment with rituximab compared to placebo … Recruiting
  2024-517667-23-00 Phase II 4 countries Oslo University Hospital HF

Showing 1–24 of 193 trials